Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
RBC Capital Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI)
May 31, 2024 6:11 AM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $96.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI).
The analyst comments "With the second ph.III MDD study, Study 502, just weeks away, and recent investor feedback suggesting that some may be cautious... More
